LSHGD: A database for human leprosy susceptible genes  by George Priya Doss, C. et al.
Genomics 100 (2012) 162–166
Contents lists available at SciVerse ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /ygenoLSHGD: A database for human leprosy susceptible genes
C. George Priya Doss a,⁎, N. Nagasundaram b, Jain Srajan b, Chakraborty Chiranjib b
a Medical Biotechnology Division, School of Biosciences and Technology, Center for Nanobiotechnology, VIT University, Vellore 632014, Tamil Nadu, India
b School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India⁎ Corresponding author at: VIT University, Vellore 63
E-mail addresses: georgecp77@yahoo.co.in, georgep
(C. George Priya Doss).
0888-7543/$ – see front matter © 2012 Elsevier Inc. All
doi:10.1016/j.ygeno.2012.06.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 March 2012
Accepted 23 June 2012
Available online 30 June 2012
Keywords:
Leprosy
Human
SNPs
DatabaseStudies aiming to explore the involvement of host genetic factors to determine susceptibility to develop dis-
ease and individual's response to the infection with Mycobacterium leprae have increased in recent years. To
address this issue, we have developed a Leprosy Susceptible Human Gene Database (LSHGD) to integrate lep-
rosy and human associated 45 genes by profound literature search. This will serve as a user-friendly and in-
teractive platform to understand the involvement of human polymorphisms (SNPs) in leprosy, independent
genetic control over both susceptibility to leprosy and its association with multi-drug resistance ofM. leprae.
As the ﬁrst human genetic database in leprosy it aims to provide information about the associated genes,
corresponding protein sequences, available three dimensional structures and polymorphism related to lepro-
sy. In conclusion, this will serve as a multifunctional valuable tool and convenient information platform
which is freely available at http://www.vit.ac.in/leprosy/leprosy.htm and enables the user to retrieve infor-
mation of their interest.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
The ﬁeld of human genetics of infectious diseases aims to deﬁne the
genetic variations accounting for inter-individual variability in the
course of human infections [1]. Leprosy (Hansen's disease) is a chronic
granulomatous infectious disease of human whose etiological agent,
Mycobacterium leprae, was identiﬁed byG. H. A. Hansen in the 19th cen-
tury. In 2011, therewere new cases reported, predominantly in Asia, Af-
rica, and Latin America [2]. According to ofﬁcial reports received from
WHO during 2011 from 130 countries and territories, the global regis-
tered prevalence of leprosy at the beginning of 2011 stood at 192,246
cases, while the number of new cases detected during 2010 was
228,474 (excluding the small number of cases in Europe). Leprosy is
an unusual disease in many aspects, not the least of which is that, de-
spite effective multi-drug therapy, the steady state number of leprosy
cases is about equal to the annual number of new cases. These numbers
are evidence of a high transmission rate. Until themodes and sources of
transmission are well understood, it is unlikely that we will be able to
interfere with the transmission or be able to eradicate this disease. Lep-
rosy is primarily a disease of the skin and peripheral nervous system.
There were also studies that involved the eyes, bone, lymph nodes,
nasal structures, and testes [3]. The Ridley–Jopling classiﬁcation uses
histopathological and clinical features and the bacteriological index as
well. It classiﬁes leprosy in tuberculoid (TT), borderline tuberculoid
(BT), borderline (BB), borderline-lepromatous (BL), and lepromatous2014, Tamil Nadu, India.
riyadoss@vit.ac.in
rights reserved.(LL) categories. In another classiﬁcation byWHO,multibacillary leprosy
includes the lepromatous (LL), borderline lepromatous (BL), and bor-
derline (BB) forms, and paucibacillary leprosy encompasses the tuber-
culoid (TT) and borderline tuberculoid (BT) forms [4]. During the past
years, few studies aiming to explore the host susceptibility to leprosy
have been explored and published. The results of epidemiological stud-
ies (twin studies and complex segregation analyses) [5–7] and
genome-wide analysis (linkage and association) [8] in leprosy infection
clearly indicated the involvement of host genetic factors to determine
susceptibility to develop the disease and the individual's response to
the infection with M. leprae. Host genetic factors may therefore largely
determine which exposed individuals develop disease. Several studies
indicate that leprosy pathogenesis is a three-step process (i) group of
genes controls susceptibility to infection, (ii) different genes control
the clinical manifestation of disease, and (iii) genes inﬂuencing the de-
velopment, in a proportion of affected individuals, of leprosy reversal
reaction type 1 (RR1). A recent human genome-wide linkage or associ-
ation studies have observed a signiﬁcant association with or linked to
leprosy in various genes C3, C4B, CCDC122, CCL3, CCL5, CFB, COL3A1,
CR1, CTLA4, DEFB1, FCN2, HLA-DQA1, HLA-DQB1, HLA-DRB1, HSPA1A,
ICAM1, IFNG, IL10, IL12B, IL12RB1, IL12RB2, LACC1, LAMA2, LRRK2, LTA,
LTA4H, MBL2, MICA, MICB, MRC1, NOD2, PACRG, PARK2, PGL1/SDHD,
RIPK2, SLC11A1, TAP1, TIRAP, TLR1, TLR2, TLR4, TNF, and TNFSF15,
[5,9–11]. Recent advances in high-throughput genotyping, next genera-
tion sequencing, and very high-density microarrays have generated a
tremendous amount of human genetic variation data associated with
human traits and diseases especially Single Nucleotide Polymorphisms
(SNPs), Copy Number Variations (CNVs), and Insertions and deletions
(Indels). There were quite a lot of studies that have reported the direct
Table 1
List of leprosy susceptible human genes.
Gene
symbol
Chromosomal
position
Description Reference
C2 6p21.33 Complement component 2 [15]
C3 19p13.3 Complement component 3 [16]
C4B 6p21.33 C4b-binding protein [17]
CCDC122 13q14.11 Coiled-coil domain containing 122 [18]
CCL3 17q12 Chemokine (C\C motif) ligand 3 [19]
CCL5 17q11 Chemokine (C\C motif) ligand 5 [20]
CFB 6p21.33 Complement factor B [21]
COL3A1 2q32.2 Collagen, type III, alpha 1 [22]
CR1 1q32.2 Complement receptor 1 [23]
CTLA4 2q33.2 Cytotoxic t-lymphocyte antigen 4 [24]
DEFB1 8p23.1 Defensin, beta 1 [25]
FCN2 9q34.3 Ficolin-2 [26]
HLA-DQA1 6p21.3 HLA class II histocompatibility antigen, DQ
alpha 1
[27]
HLA-DQB1 6p21.3 HLA class II histocompatibility antigen, DQ
beta 1
[28]
HLA-DRB1 6p21.32 HLA class II histocompatibility antigen, DR
beta 1
[29]
HSPA1A 6p21.33 Heat shock 70 kDa protein 1A [30]
ICAM1 19p13.2 Intercellular adhesion molecule 1 [31]
IFNG 12q14 Interferon-gamma (IFN-γ) [32]
IL10 1q31–q32 Interleukin-10 [33]
IL12B 5q33.3 Human interleukin 12 [34]
IL12RB1 19p13.11 Interleukin 12 receptor, beta 1 [35]
IL12RB2 1p31.3 Interleukin 12 receptor, beta 2 [36]
LACC1 13q14.11 Laccase (multicopper oxidoreductase)
domain containing 1
[18]
LAMA2 6q22–q23 Laminin subunit alpha-2 [37]
LRRK2 12q12 Leucine-rich repeat kinase 2 [38]
LTA 6p21.3 Lymphotoxin-alpha [39]
LTA4H 12q22 Leukotriene A4 hydrolase [40]
MBL2 10q11.2 Mannose-binding lectin [41]
MICA 6p21.33 MHC class I polypeptide-related sequence [42]
MICB 6p21.33 MHC class I polypeptide-related sequence B [43]
MRC1 10p12.33 Mannose receptor, C type 1 [44]
NOD2 16q21 Nucleotide-binding oligomerization
domain-containing protein 2
[45]
PACRG 6q26 Parkin coregulated gene [46]
PARK2 6q25.2–q27 Parkinson protein 2, E3 ubiquitin protein
ligase
[47]
PGL1/
SDHD
11q23 Succinate dehydrogenase complex
subunit D
[48]
RIPK2 8q21 Receptor-interacting serine/
threonine–protein kinase 2
[49]
SLC11A1 2q35 Solute carrier family 11 (proton-coupled
divalent metal ion transporters), member 1
[50]
TAP1 6p21.3 Antigen peptide transporter 1 [51]
TIRAP 11q24.2 Toll-interleukin 1 receptor [52]
TLR1 4p14 Toll-like receptor 1 [53]
TLR2 4q32 Toll-like receptor 2 [53]
TLR4 9q33.1 Toll-like receptor 4 [53]
TNF 6p21.33 Tumor necrosis factor-alpha [54]
TNFSF15 9q32 Tumor necrosis factor (ligand)
superfamily, member 15
[55]
VDR 12q13 Vitamin D (1,25-dihydroxyvitamin D3)
receptor
[56]
163C. George Priya Doss et al. / Genomics 100 (2012) 162–166involvement of SNPs in host genetics susceptibility to leprosy. SNPs pro-
vide an opportunity to understand the association between genotype
and phenotype in a much broader manner. These mounting studies on
SNPs insist their role in better understanding the resultant phenotypic
variations among individuals with an endeavor towards new drug
design and development. Mapping of SNPs to protein domains and an-
alyzing at the structural level will reveal the full extent to which they
can alter the interactivity of proteins. To understand the key structural
changes induced by SNPs, we have included three dimensional (3D)
structures of the corresponding proteins in this database. Although
human associated studies related to leprosy have received great atten-
tion from experimental researchers; there is no single comprehensive
database to address human leprosy associated gene information. The
amount of genetic data generating will also increase drastically in the
coming years. To address this issue the need for a comprehensive and
well organized collection of genetic data frommultiple published stud-
ies is urgently needed to provide information in one cluster. Currently
there are few databases available related to leprosy such as The Leprosy
VNTR Database [12], the Leprosy—Mycobacterium Leprae Database
[13], and the Database of Drug Targets for Resistant Pathogens
(DDTRP) [14] stating the information related to M. leprae and its drug
resistance. In this present study, we describe a newweb based interface
called LSHGD which provides detailed information for researchers who
are interested in analyzing the involvement and association of human
genome in leprosy. Our main urge is to provide a convenient informa-
tion platform for molecular epidemiologists and clinicians working on
leprosy. The information about the 45 leprosy susceptible human
genes [15–56] is shown in Table 1. A primary function of the database
is to provide a way of identifying associated SNPs that are likely to
have an impact on molecular function. As the ﬁrst database, freely ac-
cessible LSHGD aims to provide comprehensive sets of genetic informa-
tion both at the sequence and structural levels for extending functional
analysis.
2. Data collection
The main goal of our presented work is to develop an interface that
provides a direct link between leprosy and human associated genes.
The gene information regarding human leprosy susceptible genes
[15–56] are provided in Table 1. The data contents can scale up in two
ways. (i) The literature information on the impact of human genes and
its association with leprosy were compiled from published literatures
according to Pub Med (http://www.ncbi.nlm.nih.gov/PubMed/), OMIM
(http://www.ncbi.nlm.nih.gov/omim/), and UniProtKB (http://www.
uniprot.org/) [57]. OMIM contains textual information, pictures, and ref-
erence information. It also contains copious links to NCBI's Entrez data-
base of MEDLINE articles and sequence information. UniProt was used
to validate the involvement of gene in mutation; where this gene is im-
plicated: diseases, a selected bibliography with hyperlinks to MEDLINE
abstracts. (ii) The genomic information types include genes, chromo-
somal regions, natural variants (SNPs), associated proteins and their
pathways, etc. The SNP information of associated genes was retrieved
from the NCBI dbSNP (http://www.ncbi.nlm.nih.gov/snp/). The annotat-
ed sequence is required to determine the functional class (nsSNP,
cds-synon, UTR, and intronic) of the SNP. Nucleotide coordinates (nu-
merical position of a nucleotide in a gene sequence) and genotypic vari-
ation information were also obtained from this sequence. We retrieved
related information from Public databases and gene annotation includes
NCBI [58], OMIM [57], UniProt [59], Ensembl [60], PDB [61], HGNC [62]
and KEGG [63].
2.1. Database design
Weprovide an intuitive, well organized and user friendlyweb inter-
face that allows users to explore the detailed information of leprosy
susceptible human genes. It includes gene name, gene ID, chromosomenumber, chromosomal position, chromosomal orientation, gene func-
tion, taxonomic identiﬁer, RefSeq_protein, RefSeq_mRNA, OMIM ID,
HGNC ID, Pub Med ID, genotypic variation, residue change, function
class, SNP reference, associated protein, associated PDB ID, UniProt ID,
and associated pathways. Majorly, sequence information was incorpo-
rated from NCBI (DNA), protein related information from UniProt and
protein structures from PDB. Clicking links leads to more detailed
information.
2.2. LSHGD organization and system design
Upon accessing LSHGD (Link: http://www.vit.ac.in/leprosy/leprosy.
htm) a click on the ﬁrst interactive button named “Home” introduces
the user about the database. A click on the second interactive button
164 C. George Priya Doss et al. / Genomics 100 (2012) 162–166named “Gene Database” allows the user to speciﬁcally choose the type
of information from the check box menu that includes gene informa-
tion, chromosomal information, associated protein information, and
natural variants information from the database. A click on the third in-
teractive button named “Classiﬁcation of Gene”, allows the user to visu-
alize the classiﬁcation of human genes susceptible to leprosy based on
associated protein mechanisms. A click on the last interactive button
named “Associated protein study” allows the user to ﬁnd several
other protein associated studies in different stages of leprosy. A click
on the last interactive button named “Link to Other Database” allows
user to link other related databases Leprosy—Mycobacterium Leprae
Database [13], and Database of Drug Targets for Resistant Pathogens
(DDTRP). The following interfaces are displayed in Fig. 1. LSHGD con-
sists of three major software components: an Apache HTTP server, a
MySQL database and an Aspx script. The back end data analysis pro-
grams were written in asp script using the Microsoft Visual Studio
2008 tool.
2.3. Database implementation
A maximum of 45 genes are displayed in the interface. In gene
information the interface provides related information such as
Gene Symbol, Gene Name, Gene Function, Entrez Gene ID,
RefSeq_Protein, RefSeq_mRNA, OMIM_ID, PubMed_ID, HGNC_ID,
Primary Reference related to leprosy susceptibility, population
studied, pathway Information and other cross references. Pathway
information for each gene allows the user to identify disease relat-
ed and associated pathways. Ethnicity will provide information
about the predisposition of leprosy genes in different populations.
Similarly, Gene_Name, Gene_ID, Chromosome_Number, Chromo-
somal_Position and Orientation in Chromosomal Information
have been provided. These information will deﬁnitely provide the
user the information about susceptibility of genes in a speciﬁc
chromosomal region. Notably, gene information and chromosome
information will serve as genomic platform for database users. To
explore the possible relationships between genes and diseases we
have incorporated information about natural variants. However,
only a small subset of SNP information has been documented. It isFig. 1. Overview of the structural andeasy to determine a preliminary proﬁle of the relationship between
genes and diseases using the information such as Gene Symbol,
Entrez Gene ID, Associated SNP, Genotypic Variation, Residue
Change, Functional Annotation, Consequence of Transcript and
SNP Associated with other Disease. Information such as functional
annotation and consequence of transcript encoded have been pro-
vided for the signiﬁcant SBNPs by GWAS and pathway information
for each gene in the natural variants and gene information inter-
face of the revised database. Similarly, Gene Name, Associated pro-
tein, Chromosomal position, UniProt_ID, Associated_PDB_ID and
Associated_Pathway in protein information exist. From this natural
variants and protein information result table, the user can interlink
SNP associated information at the structural level. These interfaces
created in this database will satisfy the demands of the scientiﬁc
community by providing in depth knowledge about leprosy associ-
ation with human variants.
2.4. Designed instruction for users
The freely accessible LSHGD available at http://www.vit.ac.in/
leprosy/leprosy.htm aims to provide a comprehensive set of genetic
information both at the sequence and structural levels for extending
functional analysis. The database is composed of ﬁve interactive but-
tons in the main display (Fig. 2) and explained their functions by con-
sidering TLR1 as example.
(i) Main Page: the database is composed of ﬁve interactive but-
tons in the main display namely
Home, Gene Database, Classiﬁcation of genes, Associated pro-
tein study and Link to other databases. Home is the main
page of the database. By clicking, the user can access the sum-
marized introduction about the database (Fig. 2A).
(ii) Gene Database: This represents the main characteristics of 45
leprosy susceptible human genes. Search for genes in LSHGD
by using the drop down menu provided in the interface.
From this page the user has the option of retrieving informa-
tion of their choice such as Gene Information (Fig. 2B), Chro-
mosomal Information (Fig. 2C), Natural Variants Informationfunctional workﬂows of LSHGD.
Fig. 2. Snapshot of LSHGD to access and analyze the data associated with leprosy genes. A) Home page of the LSHGD, B) Gene Information, C) Chromosomal Information, D) Natural
Variants Information, E) Protein Information, and F) Associated protein study.
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buttons. These information will provide in depth knowledge
about the gene function, population studied, SNP information,
annotation, consequence of transcript, primary reference asso-
ciated with the disease and other cross references.
(iii) Classiﬁcation of genes: This page displays the classiﬁcation of 45
genes namely Innate Immune Receptors Genes (6), Cytokines
Genes (3), Transport Genes (1), Tissue-Speciﬁc Markers Genes
(1), Innate Immune Effectors Molecules and Serum Proteins
Genes (3), and Other Candidate Genes (31).
(iv) Associated protein studies: This page (Fig. 2F) represents other
associated proteins in different stages of leprosy namely LL, BL,
BB, TT, BT, Reversal reactions (RRs) and Erythema nodosum
leprosum (ENL).
(v) Link to other databases: This page displays two interlinked da-
tabase links which will be helpful in understanding multi‐drug
resistance in leprosy.3. Future improvement
As the amount of genomic information generatingwill be increasing
drastically in the coming years, we will continuously collect the latest
gene and SNP related data disease data sets to keep up-to-date. In the
future we would like to improvise our database in three main ways.
One is to further provide link gene symbol to their corresponding acces-
sion numbers inNCBI (NP for protein andNM formRNA). Next is to pro-
vide link to PDB ID information. Lastly, the incorporation of in silico tool
prediction results into database will be able to classify SNPs pathogenic
from neutral ones. We assure this information will deﬁnitely will makea way for genotype–phenotype researches as well as pharmacogenetics
studies.
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